Journal of Clinical Oncology, Vol 8, 813-819, Copyright © 1990 by American Society of Clinical Oncology
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
BD Cheson, PA Cassileth, DR Head, CA Schiffer, JM Bennett, CD Bloomfield, R Brunning, RP Gale, MR Grever and MJ Keating
Clinical Investigations Branch, National Cancer Institute, Bethesda, MD 20892.
The National Cancer Institute (NCI) sponsored a workshop to develop a set
of standardized diagnostic and response criteria for acute myeloid leukemia
(AML) clinical trials. The French-American-British (FAB) classification was
retained for diagnosing AML, with the addition of patients with bone marrow
morphologic features of a myelodysplastic syndrome and less than 30% bone
marrow blasts, but with greater than or equal to 30% blasts in the
peripheral blood. In this report, there are four important subgroups of AML
not defined in the FAB classification that are discussed: undifferentiated
acute leukemia, MO (AML lacking definitive myeloid differentiation by
morphology or conventional cytochemistry but with ultrastructural or
immunophenotypic evidence for AML), mixed lineage leukemia, and
hypocellular AML. Definitions of response for clinical trials are presented
to facilitate comparisons among different studies. Complete remission is
considered the only response worth reporting in phase III trials, since
lesser responses do not improve survival. Partial remissions may be of
interest to identify active new agents in phase I and II studies.
Monoclonal antibodies and cytogenetic studies are not part of the routine
assessment of remission or reassessment at relapse, and their role in the
evaluation of patients with AML is currently being evaluated in clinical
trials. Although we recognize that some of the definitions in this report
are arbitrary, generalized use of these guidelines will make results of
clinical trials more comparable and interpretable.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Kelaidi, S. Chevret, S. De Botton, E. Raffoux, A. Guerci, X. Thomas, A. Pigneux, T. Lamy, F. Rigal-Huguet, S. Meyer-Monard, et al.
Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience
J. Clin. Oncol.,
June 1, 2009;
27(16):
2668 - 2676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. van der Weide, S. D.P.W.M. de Jonge-Peeters, F. Kuipers, E. G.E. de Vries, and E. Vellenga
Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples
Clin. Cancer Res.,
May 1, 2009;
15(9):
3076 - 3083.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fey, M. Dreyling, and On behalf of the ESMO Guidelines Working Group
Acute myeloblastic leukemia in adult patients: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv100 - iv101.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. F. Schlenk, K. Dohner, M. Kneba, K. Gotze, F. Hartmann, F. del Valle, H. Kirchen, E. Koller, J. T. Fischer, L. Bullinger, et al.
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Haematologica,
January 1, 2009;
94(1):
54 - 60.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. H. Metzeler, M. Hummel, C. D. Bloomfield, K. Spiekermann, J. Braess, M.-C. Sauerland, A. Heinecke, M. Radmacher, G. Marcucci, S. P. Whitman, et al.
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia
Blood,
November 15, 2008;
112(10):
4193 - 4201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Baer, S. L. George, M. A. Caligiuri, B. L. Sanford, S. M. Bothun, K. Mrozek, J. E. Kolitz, B. L. Powell, J. O. Moore, R. M. Stone, et al.
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720
J. Clin. Oncol.,
October 20, 2008;
26(30):
4934 - 4939.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Paschka, G. Marcucci, A. S. Ruppert, S. P. Whitman, K. Mrozek, K. Maharry, C. Langer, C. D. Baldus, W. Zhao, B. L. Powell, et al.
Wilms' Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
October 1, 2008;
26(28):
4595 - 4602.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. B. Klisovic, W. Blum, X. Wei, S. Liu, Z. Liu, Z. Xie, T. Vukosavljevic, C. Kefauver, L. Huynh, J. Pang, et al.
Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Clin. Cancer Res.,
June 15, 2008;
14(12):
3889 - 3895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Rizzieri, E. Feldman, J. F. DiPersio, N. Gabrail, W. Stock, R. Strair, V. M. Rivera, M. Albitar, C. L. Bedrosian, and F. J. Giles
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res.,
May 1, 2008;
14(9):
2756 - 2762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al.
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Clin. Cancer Res.,
March 1, 2008;
14(5):
1446 - 1454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wandt, U. Schakel, F. Kroschinsky, G. Prange-Krex, B. Mohr, C. Thiede, U. Pascheberg, S. Soucek, M. Schaich, and G. Ehninger
MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients
Blood,
February 15, 2008;
111(4):
1855 - 1861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J.M. de Jonge, A. C. Weidenaar, A. ter Elst, H. M. Boezen, F. J.G. Scherpen, J. C.A. Bouma-ter Steege, G. J.L. Kaspers, B. F. Goemans, U. Creutzig, M. Zimmermann, et al.
Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia
Clin. Cancer Res.,
February 1, 2008;
14(3):
924 - 930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ades, M. A. Sanz, S. Chevret, P. Montesinos, P. Chevallier, E. Raffoux, E. Vellenga, A. Guerci, A. Pigneux, F. Huguet, et al.
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results
Blood,
February 1, 2008;
111(3):
1078 - 1084.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Montesinos, I. Lorenzo, G. Martin, J. Sanz, M. L. Perez-Sirvent, D. Martinez, G. Orti, L. Algarra, J. Martinez, F. Moscardo, et al.
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
Haematologica,
January 1, 2008;
93(1):
67 - 74.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. DeAngelo, D. Yu, J. L. Johnson, S. E. Coutre, R. M. Stone, A. T. Stopeck, J. P. Gockerman, B. S. Mitchell, F. R. Appelbaum, and R. A. Larson
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
Blood,
June 15, 2007;
109(12):
5136 - 5142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wetzler, B. L. Sanford, J. Kurtzberg, D. DeOliveira, S. R. Frankel, B. L. Powell, J. E. Kolitz, C. D. Bloomfield, and R. A. Larson
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
Blood,
May 15, 2007;
109(10):
4164 - 4167.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Lehrnbecher, M. Zimmermann, D. Reinhardt, M. Dworzak, J. Stary, and U. Creutzig
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia
Blood,
February 1, 2007;
109(3):
936 - 943.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ades, S. Chevret, E. Raffoux, S. de Botton, A. Guerci, A. Pigneux, A. M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, et al.
Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group
J. Clin. Oncol.,
December 20, 2006;
24(36):
5703 - 5710.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Knapper, A. K. Burnett, T. Littlewood, W. J. Kell, S. Agrawal, R. Chopra, R. Clark, M. J. Levis, and D. Small
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Blood,
November 15, 2006;
108(10):
3262 - 3270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Creutzig, M. Zimmermann, T. Lehrnbecher, N. Graf, J. Hermann, C. M. Niemeyer, A. Reiter, J. Ritter, M. Dworzak, J. Stary, et al.
Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98
J. Clin. Oncol.,
September 20, 2006;
24(27):
4499 - 4506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. W.L. Yee, Z. Zeng, M. Konopleva, S. Verstovsek, F. Ravandi, A. Ferrajoli, D. Thomas, W. Wierda, E. Apostolidou, M. Albitar, et al.
Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res.,
September 1, 2006;
12(17):
5165 - 5173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrozek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, J. W. Vardiman, A. J. Carroll, et al.
Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
August 20, 2006;
24(24):
3904 - 3911.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Langebrake, U. Creutzig, M. Dworzak, O. Hrusak, E. Mejstrikova, F. Griesinger, M. Zimmermann, and D. Reinhardt
Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group
J. Clin. Oncol.,
August 1, 2006;
24(22):
3686 - 3692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Wilson, G. S. Davidson, S. B. Martin, E. Andries, J. Potter, R. Harvey, K. Ar, Y. Xu, K. J. Kopecky, D. P. Ankerst, et al.
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction
Blood,
July 15, 2006;
108(2):
685 - 696.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Farag, K. J. Archer, K. Mrozek, A. S. Ruppert, A. J. Carroll, J. W. Vardiman, M. J. Pettenati, M. R. Baer, M. B. Qumsiyeh, P. R. Koduru, et al.
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
Blood,
July 1, 2006;
108(1):
63 - 73.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Gore, S. Baylin, E. Sugar, H. Carraway, C. B. Miller, M. Carducci, M. Grever, O. Galm, T. Dauses, J. E. Karp, et al.
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Cancer Res.,
June 15, 2006;
66(12):
6361 - 6369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Levine, A. Tulpule, D. I. Quinn, G. Gorospe III, D. L. Smith, L. Hornor, W. D. Boswell, B. M. Espina, S. G. Groshen, R. Masood, et al.
Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy
J. Clin. Oncol.,
April 10, 2006;
24(11):
1712 - 1719.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-T. Krauth, S. Florian, A. Bohm, K. Sonneck, H. Agis, P. Samorapoompichit, A. W. Hauswirth, W. R. Sperr, and P. Valent
Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5
J. Immunol.,
February 1, 2006;
176(3):
1759 - 1768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Oki, H. M. Kantarjian, X. Zhou, J. Cortes, S. Faderl, S. Verstovsek, S. O'Brien, C. Koller, M. Beran, B. N. Bekele, et al.
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
Blood,
February 1, 2006;
107(3):
880 - 884.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Marcucci, C. D. Baldus, A. S. Ruppert, M. D. Radmacher, K. Mrozek, S. P. Whitman, J. E. Kolitz, C. G. Edwards, J. W. Vardiman, B. L. Powell, et al.
Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
December 20, 2005;
23(36):
9234 - 9242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Gale, R. Hills, A. R. Pizzey, P. D. Kottaridis, D. Swirsky, A. F. Gilkes, E. Nugent, K. I. Mills, K. Wheatley, E. Solomon, et al.
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
Blood,
December 1, 2005;
106(12):
3768 - 3776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. van der Holt, B. Lowenberg, A. K. Burnett, W. U. Knauf, J. Shepherd, P. P. Piccaluga, G. J. Ossenkoppele, G. E. G. Verhoef, A. Ferrant, M. Crump, et al.
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
Blood,
October 15, 2005;
106(8):
2646 - 2654.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Marcucci, K. Mrozek, A. S. Ruppert, K. Maharry, J. E. Kolitz, J. O. Moore, R. J. Mayer, M. J. Pettenati, B. L. Powell, C. G. Edwards, et al.
Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
August 20, 2005;
23(24):
5705 - 5717.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-C. Chen, C.-F. Yang, M.-H. Yang, K.-D. Lee, W.-K. Kwang, J.-Y. You, Y.-B. Yu, C.-H. Ho, C.-H. Tzeng, W.-K. Chau, et al.
Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia
Ann. Onc.,
August 1, 2005;
16(8):
1366 - 1373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Testi, A. Biondi, F. L. Coco, M. L. Moleti, F. Giona, M. Vignetti, G. Menna, F. Locatelli, A. Pession, E. Barisone, et al.
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children
Blood,
July 15, 2005;
106(2):
447 - 453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. K. Kelly, O. A. O'Connor, L. M. Krug, J. H. Chiao, M. Heaney, T. Curley, B. MacGregore-Cortelli, W. Tong, J. P. Secrist, L. Schwartz, et al.
Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer
J. Clin. Oncol.,
June 10, 2005;
23(17):
3923 - 3931.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Marcucci, W. Stock, G. Dai, R. B. Klisovic, S. Liu, M. I. Klisovic, W. Blum, C. Kefauver, D. A. Sher, M. Green, et al.
Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity
J. Clin. Oncol.,
May 20, 2005;
23(15):
3404 - 3411.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. O. Moore, S. L. George, R. K. Dodge, P. C. Amrein, B. L. Powell, J. E. Kolitz, M. R. Baer, F. R. Davey, C. D. Bloomfield, R. A. Larson, et al.
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
Blood,
May 1, 2005;
105(9):
3420 - 3427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood,
February 1, 2005;
105(3):
959 - 967.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Fiedler, H. Serve, H. Dohner, M. Schwittay, O. G. Ottmann, A.-M. O'Farrell, C. L. Bello, R. Allred, W. C. Manning, J. M. Cherrington, et al.
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
Blood,
February 1, 2005;
105(3):
986 - 993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Farag, A. S. Ruppert, K. Mrozek, R. J. Mayer, R. M. Stone, A. J. Carroll, B. L. Powell, J. O. Moore, M. J. Pettenati, P. R.K. Koduru, et al.
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
January 20, 2005;
23(3):
482 - 493.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Kolitz, S. L. George, R. K. Dodge, D. D. Hurd, B. L. Powell, S. L. Allen, E. Velez-Garcia, J. O. Moore, T. C. Shea, E. Hoke, et al.
Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621
J. Clin. Oncol.,
November 1, 2004;
22(21):
4290 - 4301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Creutzig, M. Zimmermann, D. Reinhardt, M. Dworzak, J. Stary, and T. Lehrnbecher
Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98
J. Clin. Oncol.,
November 1, 2004;
22(21):
4384 - 4393.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Castaigne, S. Chevret, E. Archimbaud, P. Fenaux, D. Bordessoule, H. Tilly, T. de Revel, M. Simon, B. Dupriez, M. Renoux, et al.
Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study
Blood,
October 15, 2004;
104(8):
2467 - 2474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Creutzig and G.J.L. Kaspers
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
J. Clin. Oncol.,
August 15, 2004;
22(16):
3432 - 3433.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Nabhan, L. Rundhaugen, M. Jatoi, M. B. Riley, L. Boehlke, L. C. Peterson, and M. S. Tallman
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease
Ann. Onc.,
August 1, 2004;
15(8):
1231 - 1236.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. H. Min, J.-W. Cheong, J. Y. Kim, J. I. Eom, S. T. Lee, J. S. Hahn, Y. W. Ko, and M. H. Lee
Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia
Cancer Res.,
August 1, 2004;
64(15):
5225 - 5231.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. H. Min, J.-W. Cheong, M. H. Lee, J. Y. Kim, S. T. Lee, J. S. Hahn, and Y. W. Ko
Elevated S-Phase Kinase-Associated Protein 2 Protein Expression in Acute Myelogenous Leukemia: Its Association with Constitutive Phosphorylation of Phosphatase and Tensin Homologue Protein and Poor Prognosis
Clin. Cancer Res.,
August 1, 2004;
10(15):
5123 - 5130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Marcucci, K. Mrozek, A. S. Ruppert, K. J. Archer, M. J. Pettenati, N. A. Heerema, A. J. Carroll, P. R.K. Koduru, J. E. Kolitz, L. J. Sterling, et al.
Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461
J. Clin. Oncol.,
June 15, 2004;
22(12):
2410 - 2418.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Karp, I. Gojo, R. Pili, C. D. Gocke, J. Greer, C. Guo, D. Qian, L. Morris, M. Tidwell, H. Chen, et al.
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-{beta}-D-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab
Clin. Cancer Res.,
June 1, 2004;
10(11):
3577 - 3585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Sekeres, B. Peterson, R. K. Dodge, R. J. Mayer, J. O. Moore, E. J. Lee, J. Kolitz, M. R. Baer, C. A. Schiffer, A. J. Carroll, et al.
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia
Blood,
June 1, 2004;
103(11):
4036 - 4042.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Byrd, A. S. Ruppert, K. Mrozek, A. J. Carroll, C. G. Edwards, D. C. Arthur, M. J. Pettenati, J. Stamberg, P. R.K. Koduru, J. O. Moore, et al.
Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461
J. Clin. Oncol.,
March 15, 2004;
22(6):
1087 - 1094.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Frohling, R. F. Schlenk, I. Stolze, J. Bihlmayr, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner
CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations
J. Clin. Oncol.,
February 15, 2004;
22(4):
624 - 633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Sanz, G. Martin, M. Gonzalez, A. Leon, C. Rayon, C. Rivas, D. Colomer, E. Amutio, F. J. Capote, G. A. Milone, et al.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group
Blood,
February 15, 2004;
103(4):
1237 - 1243.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. D. Cheson, J. M. Bennett, K. J. Kopecky, T. Buchner, C. L. Willman, E. H. Estey, C. A. Schiffer, H. Doehner, M. S. Tallman, T. A. Lister, et al.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
J. Clin. Oncol.,
December 15, 2003;
21(24):
4642 - 4649.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. K. Tur, M. Huhn, T. Thepen, M. Stocker, R. Krohn, S. Vogel, E. Jost, R. Osieka, J. G. van de Winkel, R. Fischer, et al.
Recombinant CD64-Specific Single Chain Immunotoxin Exhibits Specific Cytotoxicity against Acute Myeloid Leukemia Cells
Cancer Res.,
December 1, 2003;
63(23):
8414 - 8419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. H. Estey, P. F. Thall, X. Wang, S. Verstovsek, J. Cortes, and H. M. Kantarjian
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML
Blood,
November 1, 2003;
102(9):
3097 - 3099.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Fiedler, R. Mesters, H. Tinnefeld, S. Loges, P. Staib, U. Duhrsen, M. Flasshove, O. G. Ottmann, W. Jung, F. Cavalli, et al.
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
Blood,
October 15, 2003;
102(8):
2763 - 2767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Zwaan, S. Meshinchi, J. P. Radich, A. J. P. Veerman, D. R. Huismans, L. Munske, M. Podleschny, K. Hahlen, R. Pieters, M. Zimmermann, et al.
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance
Blood,
October 1, 2003;
102(7):
2387 - 2394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Baldus, S. M. Tanner, A. S. Ruppert, S. P. Whitman, K. J. Archer, G. Marcucci, M. A. Caligiuri, A. J. Carroll, J. W. Vardiman, B. L. Powell, et al.
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
Blood,
September 1, 2003;
102(5):
1613 - 1618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Fey
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of acute myeloblastic leukaemia (AML) in adult patients
Ann. Onc.,
August 1, 2003;
14(8):
1161 - 1162.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Delaunay, N. Vey, T. Leblanc, P. Fenaux, F. Rigal-Huguet, F. Witz, T. Lamy, A. Auvrignon, D. Blaise, A. Pigneux, et al.
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup
Blood,
July 15, 2003;
102(2):
462 - 469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Raffoux, P. Rousselot, J. Poupon, M.-T. Daniel, B. Cassinat, R. Delarue, A.-L. Taksin, D. Rea, A. Buzyn, A. Tibi, et al.
Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia
J. Clin. Oncol.,
June 15, 2003;
21(12):
2326 - 2334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Smith, J. Bryant, A. DeCillis, and S. Anderson
Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience
J. Clin. Oncol.,
April 1, 2003;
21(7):
1195 - 1204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Stein, M. R. O'Donnell, M. L. Slovak, D. S. Snyder, A. P. Nademanee, P. Parker, A. Molina, G. Somlo, H. C. Fung, A. Krishnan, et al.
Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
J. Clin. Oncol.,
February 15, 2003;
21(4):
615 - 623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Rizzieri, V. K. Ibom, J. O. Moore, C. M. DeCastro, G. L. Rosner, D. J. Adams, T. Foster, N. Payne, M. Thompson, J. J. Vredenburgh, et al.
Phase I Evaluation of Prolonged-infusion Gemcitabine with Fludarabine for Relapsed or Refractory Acute Myelogenous Leukemia
Clin. Cancer Res.,
February 1, 2003;
9(2):
663 - 668.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Haferlach, C. Schoch, H. Loffler, W. Gassmann, W. Kern, S. Schnittger, C. Fonatsch, W.-D. Ludwig, C. Wuchter, B. Schlegelberger, et al.
Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies
J. Clin. Oncol.,
January 15, 2003;
21(2):
256 - 265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Marcucci, J. C. Byrd, G. Dai, M. I. Klisovic, P. J. Kourlas, D. C. Young, S. R. Cataland, D. B. Fisher, D. Lucas, K. K. Chan, et al.
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
Blood,
January 15, 2003;
101(2):
425 - 432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Tallman, J. W. Andersen, C. A. Schiffer, F. R. Appelbaum, J. H. Feusner, W. G. Woods, A. Ogden, H. Weinstein, L. Shepherd, C. Willman, et al.
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
Blood,
December 15, 2002;
100(13):
4298 - 4302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Byrd, K. Mrozek, R. K. Dodge, A. J. Carroll, C. G. Edwards, D. C. Arthur, M. J. Pettenati, S. R. Patil, K. W. Rao, M. S. Watson, et al.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Blood,
December 15, 2002;
100(13):
4325 - 4336.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Frohling, R. F. Schlenk, J. Breitruck, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
Blood,
December 15, 2002;
100(13):
4372 - 4380.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Stone
The Difficult Problem of Acute Myeloid Leukemia in the Older Adult
CA Cancer J Clin,
November 1, 2002;
52(6):
363 - 371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. T. Voso, F. D'Alo', R. Putzulu, L. Mele, A. Scardocci, P. Chiusolo, R. Latagliata, F. Lo-Coco, S. Rutella, L. Pagano, et al.
Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia
Blood,
September 26, 2002;
100(8):
2703 - 2707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Preudhomme, C. Sagot, N. Boissel, J.-M. Cayuela, I. Tigaud, S. de Botton, X. Thomas, E. Raffoux, C. Lamandin, S. Castaigne, et al.
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)
Blood,
September 26, 2002;
100(8):
2717 - 2723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. G. Ottmann, B. J. Druker, C. L. Sawyers, J. M. Goldman, J. Reiffers, R. T. Silver, S. Tura, T. Fischer, M. W. Deininger, C. A. Schiffer, et al.
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
Blood,
August 28, 2002;
100(6):
1965 - 1971.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Dohner, K. Tobis, R. Ulrich, S. Frohling, A. Benner, R. F. Schlenk, and H. Dohner
Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia Study Group Ulm
J. Clin. Oncol.,
August 1, 2002;
20(15):
3254 - 3261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Baer, S. L. George, R. K. Dodge, K. L. O'Loughlin, H. Minderman, M. A. Caligiuri, J. Anastasi, B. L. Powell, J. E. Kolitz, C. A. Schiffer, et al.
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
Blood,
July 30, 2002;
100(4):
1224 - 1232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Cragg, M. Andreeff, E. Feldman, J. Roberts, A. Murgo, M. Winning, M. B. Tombes, G. Roboz, L. Kramer, and S. Grant
Phase I Trial and Correlative Laboratory Studies of Bryostatin 1 (NSC 339555) and High-Dose 1-B-D-Arabinofuranosylcytosine in Patients with Refractory Acute Leukemia
Clin. Cancer Res.,
July 1, 2002;
8(7):
2123 - 2133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Nguyen, T. Leblanc, P. Fenaux, F. Witz, D. Blaise, A. Pigneux, X. Thomas, F. Rigal-Huguet, B. Lioure, A. Auvrignon, et al.
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup
Blood,
May 15, 2002;
99(10):
3517 - 3523.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Castro-Malaspina, R. E. Harris, J. Gajewski, N. Ramsay, R. Collins, B. Dharan, R. King, and H. J. Deeg
Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program
Blood,
March 15, 2002;
99(6):
1943 - 1951.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Rizzieri, A. J. Bass, G. L. Rosner, J. P. Gockerman, C. M. DeCastro, W. P. Petros, D. J. Adams, M. J. Laughlin, P. Davis, T. Foster, et al.
Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed or Refractory Acute Leukemia
J. Clin. Oncol.,
February 1, 2002;
20(3):
674 - 679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. B. Steins, T. Padro, R. Bieker, S. Ruiz, M. Kropff, J. Kienast, T. Kessler, T. Buechner, W. E. Berdel, and R. M. Mesters
Efficacy and safety of thalidomide in patients with acute myeloid leukemia
Blood,
February 1, 2002;
99(3):
834 - 839.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Benekli, Z. Xia, K. A. Donohue, L. A. Ford, L. A. Pixley, M. R. Baer, H. Baumann, and M. Wetzler
Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival
Blood,
January 1, 2002;
99(1):
252 - 257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. List, K. J. Kopecky, C. L. Willman, D. R. Head, D. L. Persons, M. L. Slovak, R. Dorr, C. Karanes, H. E. Hynes, J. H. Doroshow, et al.
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
Blood,
December 1, 2001;
98(12):
3212 - 3220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Jurcic, S. D. Nimer, D. A. Scheinberg, T. DeBlasio, R. P. Warrell Jr, and W. H. Miller Jr
Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia
Blood,
November 1, 2001;
98(9):
2651 - 2656.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Specchia, F. Lo Coco, M. Vignetti, G. Avvisati, P. Fazi, F. Albano, F. Di Raimondo, B. Martino, F. Ferrara, C. Selleri, et al.
Extramedullary Involvement at Relapse in Acute Promyelocytic Leukemia Patients Treated or Not With All-Trans Retinoic Acid: A Report by the Gruppo Italiano Malattie Ematologiche dell'Adulto
J. Clin. Oncol.,
October 15, 2001;
19(20):
4023 - 4028.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. San Miguel, M. B. Vidriales, C. Lopez-Berges, J. Diaz-Mediavilla, N. Gutierrez, C. Canizo, F. Ramos, M. J. Calmuntia, J. J. Perez, M. Gonzalez, et al.
Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification
Blood,
September 15, 2001;
98(6):
1746 - 1751.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. D. Kottaridis, R. E. Gale, M. E. Frew, G. Harrison, S. E. Langabeer, A. A. Belton, H. Walker, K. Wheatley, D. T. Bowen, A. K. Burnett, et al.
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
Blood,
September 15, 2001;
98(6):
1752 - 1759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Goldstone, A. K. Burnett, K. Wheatley, A. G. Smith, R. M. Hutchinson, and R. E. Clark
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
Blood,
September 1, 2001;
98(5):
1302 - 1311.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C. J. Harrison, K. Wheatley, A. K. Burnett, and A. H. Goldstone
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
Blood,
September 1, 2001;
98(5):
1312 - 1320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Stone, D. T. Berg, S. L. George, R. K. Dodge, P. A. Paciucci, P. P. Schulman, E. J. Lee, J. O. Moore, B. L. Powell, M. R. Baer, et al.
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
Blood,
August 1, 2001;
98(3):
548 - 553.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Mesters, T. Padro, R. Bieker, M. Steins, M. Kreuter, M. Goner, S. Kelsey, P. Scigalla, W. Fiedler, T. Buchner, et al.
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
Blood,
July 1, 2001;
98(1):
241 - 243.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. F. Bross, J. Beitz, G. Chen, X. H. Chen, E. Duffy, L. Kieffer, S. Roy, R. Sridhara, A. Rahman, G. Williams, et al.
Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia
Clin. Cancer Res.,
June 1, 2001;
7(6):
1490 - 1496.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
Blood,
June 1, 2001;
97(11):
3361 - 3369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Baer, C. C. Stewart, R. K. Dodge, G. Leget, N. Sule, K. Mrozek, C. A. Schiffer, B. L. Powell, J. E. Kolitz, J. O. Moore, et al.
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
Blood,
June 1, 2001;
97(11):
3574 - 3580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Creutzig, J. Ritter, M. Zimmermann, D. Reinhardt, J. Hermann, F. Berthold, G. Henze, H. Jurgens, H. Kabisch, W. Havers, et al.
Improved Treatment Results in High-Risk Pediatric Acute Myeloid Leukemia Patients After Intensification With High-Dose Cytarabine and Mitoxantrone: Results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93
J. Clin. Oncol.,
May 15, 2001;
19(10):
2705 - 2713.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Rush, Z. Dai, D. J. Smiraglia, X. Gao, F. A. Wright, M. Fruhwald, J. F. Costello, W. A. Held, L. Yu, R. Krahe, et al.
Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci
Blood,
May 15, 2001;
97(10):
3226 - 3233.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Dorr, C. Karanes, C. Spier, T. Grogan, J. Greer, J. Moore, B. Weinberger, G. Schiller, T. Pearce, M. Litchman, et al.
Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia
J. Clin. Oncol.,
March 15, 2001;
19(6):
1589 - 1599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Strauchen, M. S. Tallman, and J. M. Bennett
Criteria for the diagnosis of acute megakaryocytic leukemia
Blood,
March 15, 2001;
97(6):
1898 - 1898.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Davies, L. L. Robison, J. D. Buckley, T. Tjoa, W. G. Woods, G. A. Radloff, J. A. Ross, and J. P. Perentesis
Glutathione S-Transferase Polymorphisms and Outcome of Chemotherapy in Childhood Acute Myeloid Leukemia
J. Clin. Oncol.,
March 1, 2001;
19(5):
1279 - 1287.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|